Browse News
Filter News
Found 61,129 articles
-
Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling
6/9/2023
Inspire Medical Systems, Inc. announced today that it has received approval from the Food and Drug Administration (FDA) on an expanded indication.
-
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1
6/9/2023
Daré Bioscience, Inc. today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal administration to treat vulvovaginal atrophy (VVA) in women without the use of hormones.
-
China Approves the World's First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use
6/9/2023
On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent Protein Vaccine developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China.
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
6/9/2023
Renalytix plc today reported financial results for the fiscal third quarter ended March 31, 2023.
-
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association
6/9/2023
Keros Therapeutics, Inc. announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes, as well as preclinical data showing the potential of a research form of KER-050 to restore erythropoiesis in an animal model of myelofibrosis, at the 28th Annual Congress of the European Hematology Association, held in person and virtually June 8 through 15, 2023.
-
A class-action lawsuit from thousands of third-party payers alleges that the companies broke racketeering laws to market their diabetes drug Actos, while not disclosing its bladder cancer risk.
-
The company said Thursday it has closed $200 million in Series B financing—on top of last year’s $200 million Series A haul—to help initiate a registrational Phase II study for its lead candidate UPB-101.
-
Hyperfine, Inc. and the International Society for Magnetic Resonance in Medicine Collaborate to Enhance Global Access to MR Education
6/8/2023
Hyperfine, Inc. is proud to be the first magnetic resonance imaging technology partner in an education-centric collaboration between the International Society for Magnetic Resonance in Medicine and the Bill & Melinda Gates Foundation.
-
Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce
6/8/2023
Shineco, Inc., a provider of technologically advanced healthcare products and services, announced that in May 2023, its wholly owned subsidiary.
-
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis
6/8/2023
Ocean Biomedical , Inc. (NASDAQ: OCEA ) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD has been granted a new patent for his malaria vaccine discoveries that may be used to interdict the parasite at multiple stages in the malaria cycle.
-
Parse Biosciences Launches CRISPR Detect
6/8/2023
Parse Biosciences announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale.
-
Abivax Stock Included in MSCI Indexes
6/8/2023
Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces that as of June 1 st, 2023, its stock is represented in the MSCI Indexes.
-
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases
6/8/2023
Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases.
-
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
6/8/2023
Inventiva and Echosens announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.
-
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
6/8/2023
Innate Pharma SA is pleased to share Sanofi’s news that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.
-
Annual General Meeting 2023
6/8/2023
ObsEva SA, a biopharmaceutical company developing novel therapies for women's health, published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
-
eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings
6/8/2023
eFFECTOR Therapeutics, Inc. announced that it has closed its previously announced $8.7 million registered direct offering for the purchase and sale of an aggregate of 7,764,445 shares of its common stock, at a purchase price of $1.125 per share, priced at-the-market under Nasdaq rules.
-
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
6/8/2023
Plus Therapeutics, Inc. today announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting.
-
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
6/8/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today reported financial and corporate results for its first quarter ended March 31, 2023.
-
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
6/8/2023
Biora Therapeutics, Inc. (Nasdaq: BIOR) today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.